Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Cabozantinib s-malate by Exelixis for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
Cabozantinib s-malate is under clinical development by Exelixis and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According...
Cabozantinib s-malate by Exelixis for Esophageal Cancer: Likelihood of Approval
Cabozantinib s-malate is under clinical development by Exelixis and currently in Phase II for Esophageal Cancer. According to GlobalData, Phase...
Cabozantinib s-malate by Exelixis for Gastric Cancer: Likelihood of Approval
Cabozantinib s-malate is under clinical development by Exelixis and currently in Phase II for Gastric Cancer. According to GlobalData, Phase...
Cabometyx by Exelixis for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET): Likelihood of Approval
Cabometyx is under clinical development by Exelixis and currently in Phase III for Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET). According to GlobalData,...
Cabometyx by Exelixis for Metastatic Colorectal Cancer: Likelihood of Approval
Cabometyx is under clinical development by Exelixis and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData, Phase...
Cabozantinib s-malate by Exelixis for Penile Cancer: Likelihood of Approval
Cabozantinib s-malate is under clinical development by Exelixis and currently in Phase II for Penile Cancer. According to GlobalData, Phase...
Cabometyx by Exelixis for Solid Tumor: Likelihood of Approval
Cabometyx is under clinical development by Exelixis and currently in Phase II for Solid Tumor. According to GlobalData, Phase II...
Cabometyx by Exelixis for Non-Small Cell Lung Cancer: Likelihood of Approval
Cabometyx is under clinical development by Exelixis and currently in Phase III for Non-Small Cell Lung Cancer. According to GlobalData,...
Cabozantinib s-malate by Exelixis for Follicular Thyroid Cancer: Likelihood of Approval
Cabozantinib s-malate is under clinical development by Exelixis and currently in Phase I for Follicular Thyroid Cancer. According to GlobalData,...
Cabozantinib s-malate by Exelixis for Papillary Thyroid Cancer: Likelihood of Approval
Cabozantinib s-malate is under clinical development by Exelixis and currently in Phase I for Papillary Thyroid Cancer. According to GlobalData,...
XL-888 by Exelixis for Colorectal Cancer: Likelihood of Approval
XL-888 is under clinical development by Exelixis and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase I...
XB-002 by Exelixis for Epithelial Ovarian Cancer: Likelihood of Approval
XB-002 is under clinical development by Exelixis and currently in Phase II for Epithelial Ovarian Cancer. According to GlobalData, Phase...
XB-002 by Exelixis for Pancreatic Cancer: Likelihood of Approval
XB-002 is under clinical development by Exelixis and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase II...
XB-002 by Exelixis for Oral Cavity (Mouth) Cancer: Likelihood of Approval
XB-002 is under clinical development by Exelixis and currently in Phase II for Oral Cavity (Mouth) Cancer. According to GlobalData,...
XB-002 by Exelixis for Oropharyngeal Cancer: Likelihood of Approval
XB-002 is under clinical development by Exelixis and currently in Phase II for Oropharyngeal Cancer. According to GlobalData, Phase II...
XB-002 by Exelixis for Laryngeal Cancer: Likelihood of Approval
XB-002 is under clinical development by Exelixis and currently in Phase II for Laryngeal Cancer. According to GlobalData, Phase II...
XB-002 by Exelixis for Hypopharyngeal Cancer: Likelihood of Approval
XB-002 is under clinical development by Exelixis and currently in Phase II for Hypopharyngeal Cancer. According to GlobalData, Phase II...
XB-002 by Exelixis for Non-Small Cell Lung Cancer: Likelihood of Approval
XB-002 is under clinical development by Exelixis and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData,...
XB-002 by Exelixis for Endometrial Cancer: Likelihood of Approval
XB-002 is under clinical development by Exelixis and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase II...
Risk adjusted net present value: What is the current valuation of Exelixis's XB-002?
XB-002 is a monoclonal antibody conjugated commercialized by Exelixis, with a leading Phase II program in Esophageal Squamous Cell Carcinoma...